Semaglutide improves health‐related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6)

Date first appeared online	30/03/2020
DOI	10.1111/dom.14039
Authors	Bain S.
Journal Name	Diabetes, Obesity and Metabolism
Volume

Documents

• 54313VOR.pdf , Book, Released under the terms of a Creative Commons Attribution‐NonCommercial License (CC-BY-NC).